Dr Philip Mease shares his clinical insights for diagnosing and treating fibromyalgia and psoriatic arthritis.

UCB, a global biopharmaceutical company, today announced positive topline data from the BE BOLD trial assessing BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in adults with active psoriatic ...